Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Marinus Pharmaceuticals
company
About
Marinus Pharmaceuticals reformulates, develops, and commercializes drugs to treat neurological, psychiatric, and pain disorders.
- Branford,Connecticut,United States
- 101 - 250
- http://www.marinuspharma.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $60M
- Industries
- Biopharma,Biotechnology,Health Diagnostics,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2003
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:MRNS
- Legal Name
- Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
13
$451.86M
Marinus Pharmaceuticals has raised a total of
$451.86M
in funding over 2 rounds. Their latest funding was raised on
Nov 7, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 7, 2022 | Post-IPO Equity | $60M | — | — | — | Detail |
| Oct 31, 2022 | Post-IPO Debt | $32.50M | 1 |
|
— | Detail |
| Apr 4, 2022 | Post-IPO Equity | $1.23M | — | — | — | Detail |
| Mar 31, 2022 | Post-IPO Debt | $30M | 1 |
|
— | Detail |
| May 17, 2021 | Post-IPO Debt | $45M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
7
8
Marinus Pharmaceuticals is funded by 8 investors.
Sagard Healthcare Royalty Partners
and Oaktree Capital Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Post-IPO Debt |
|
|
Yes | Post-IPO Debt |
Bain Capital Life Sciences
|
— | Post-IPO Equity |
Canaan Partners
|
— | Series C |
Domain Associates
|
— | Series C |
Foundation Medical Partners
|
— | Series C |
Sofinnova Investments
|
— | Series C |
RMI Partners
|
— | Series Unknown |
Employee Profiles
Number of Employee Profiles
14
Marinus Pharmaceuticals has 14 current employee profiles, including
Board member Harry T. Rein
Board member
Board member
Board member
Executive
Board member
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
